News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
103,896 Results
Type
Article (6448)
Company Profile (11)
Press Release (97437)
Section
Business (41503)
Career Advice (381)
Deals (7376)
Drug Delivery (51)
Drug Development (9948)
Employer Resources (33)
FDA (1772)
Job Trends (1954)
News (60105)
Policy (4385)
Tag
Academia (277)
Alliances (6000)
Alzheimer's disease (153)
Approvals (1756)
Artificial intelligence (27)
Bankruptcy (67)
Best Places to Work (1544)
Cancer (155)
Cardiovascular disease (24)
Career advice (326)
Cell therapy (45)
Clinical research (7773)
Collaboration (70)
COVID-19 (344)
C-suite (42)
Data (153)
Diabetes (83)
Diagnostics (851)
Drug pricing (46)
Earnings (17255)
Employer resources (31)
Events (11427)
Executive appointments (148)
FDA (1856)
Funding (87)
Gene therapy (37)
GLP-1 (407)
Government (643)
Healthcare (3213)
Infectious disease (360)
Inflammatory bowel disease (26)
Interviews (43)
IPO (3140)
Job creations (436)
Job search strategy (295)
Layoffs (66)
Legal (1107)
Lung cancer (23)
Manufacturing (51)
Medical device (2382)
Medtech (2383)
Mergers & acquisitions (4278)
Metabolic disorders (254)
Neuroscience (200)
NextGen Class of 2024 (1017)
Non-profit (452)
Northern California (296)
Obesity (167)
Opinion (54)
Patents (23)
People (16670)
Phase I (2440)
Phase II (3572)
Phase III (2766)
Pipeline (123)
Podcasts (26)
Policy (31)
Postmarket research (210)
Preclinical (890)
Radiopharmaceuticals (63)
Rare diseases (41)
Real estate (610)
Regulatory (2872)
Research institute (316)
Resumes & cover letters (51)
Series A (20)
Southern California (203)
Startups (612)
The Weekly (24)
United States (2269)
Vaccines (79)
Weight loss (171)
Date
Last 7 days (121)
Last 30 days (651)
Last 365 days (6843)
2024 (6320)
2023 (7096)
2022 (9815)
2021 (9963)
2020 (8991)
2019 (7041)
2018 (5538)
2017 (5368)
2016 (4939)
2015 (5627)
2014 (4220)
2013 (3231)
2012 (3486)
2011 (3655)
2010 (3274)
Location
Africa (122)
Arizona (22)
Asia (6924)
Australia (1119)
California (572)
Canada (284)
China (47)
Colorado (47)
Connecticut (30)
Europe (15737)
Florida (84)
Georgia (24)
Illinois (35)
Indiana (57)
Maryland (134)
Massachusetts (346)
Michigan (22)
Minnesota (30)
New Jersey (285)
New York (125)
North Carolina (142)
Northern California (296)
Ohio (27)
Pennsylvania (118)
South America (187)
Southern California (203)
Texas (81)
Washington State (32)
103,896 Results for "novo holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
November 6, 2024
·
3 min read
·
Tristan Manalac
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
Manufacturing
Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector
Novo Holdings’ acquisition of Catalent has ignited concerns from industry stakeholders, who fear that the consolidation could limit competition, but there is also the possibility that the deal could represent an opportunity for smaller-scale CDMOs to find new partners.
November 13, 2024
·
4 min read
·
Ben Hargreaves
Weight loss
Novo’s Wegovy Launched in China at a Fraction of US Price
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine for about $193.27 for a one-month supply.
November 18, 2024
·
1 min read
·
Annalee Armstrong
GLP-1
FDA Says All Doses of Novo’s Ozempic, Wegovy Now Available
Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up with demand for the blockbuster GLP-1 drugs.
October 31, 2024
·
2 min read
·
Tristan Manalac
Editorial
Lilly vs. Novo: The ‘He Said, She Said’ Row About Catalent’s GLP-1 Work
With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.
November 8, 2024
·
4 min read
·
Greg Slabodkin
Editorial
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
October 11, 2024
·
3 min read
·
Greg Slabodkin
GLP-1
Novo’s Wegovy Comparable to Madrigal’s Rezdiffra in Phase III MASH Trial: Analysts
In part 1 of the pivotal ESSENCE trial, Novo Nordisk’s weight loss drug Wegovy demonstrated “statistically significant and superior improvement” in liver fibrosis in patients with metabolic dysfunction–associated steatohepatitis.
November 1, 2024
·
3 min read
·
Heather McKenzie
Mergers & acquisitions
Unions, Public Interest Groups Call on FTC to Challenge Novo Holdings-Catalent Acquisition
Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging FTC Chair Lina Khan to block the merger if it violates antitrust laws.
October 18, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
1 of 10,390
Next
